Merck's giant migraine over the Vytorin data is spilling into one of its development programs. Researchers halted enrollment in a late-stage study of the cholesterol drug Cordaptive to ponder results from similar trials as well as the lessons learned from Vytorin. The trial will continue with 300 volunteers instead of the planned 900. Report [1]
Links:
[1] http://www.fiercebiotech.com/press-releases/update-merck-co-inc-mrk-s-investigational-extended-release-niacin-laropiprant-patient